SEARCH:   Advanced

Blood, 15 September 2008, Vol. 112, No. 6, pp. 2585. This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hagenbeek, A. Search for Related Content PubMed Articles by Hagenbeek, A. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CORRESPONDENCE Response: Multiple administrations of the fully human monoclonal antibody Ofatumumab We thank Tod W. Speer, MD, for his valuable comments, which basically underline what we have stated in our paper.1 Multiple administrations of a fully human monoclonal antibody such as Ofatumumab in immunocompetent patients would not likely induce antibody formation—and thereby make the treatment ineffective—because of the lack of immunogenicity. That this might offer significant advantages above murine or chimeric antibodies, for instance, after labeling the antibody with an isotope and performing repeated radioimmunotherapy, remains to be established by the appropriate clinical studies. In that regard, Dr Speer comes forward with interesting theoretical calculations in terms of schedules inducing the most effective cell kill. Again, these hypotheses need to be proven by clinical trials.    Authorship Top Authorship Reference   Conflict of interest disclosure: The author declares no competing financial interests. Correspondence: Anton Hagenbeek, MD, PhD, Department of Hematology (G03.550), University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; e-mail: a.hagenbeek{at}umcutrecht.nl. Anton Hagenbeek    Reference Top Authorship Reference   Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486–5495.[Abstract/Free Full Text] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Fully human monoclonal antibodies and targeted radionuclide therapy Tod W. Speer Blood 2008 112: 2584-2585. [Full Text] [PDF] First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Flensburg, Jørgen Petersen, Nedjad Losic, and John Radford Blood 2008 111: 5486-5495. [Abstract] [Full Text] [PDF] This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hagenbeek, A. Search for Related Content PubMed Articles by Hagenbeek, A. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020